Volume 11, Issue 1 (2025)
CJP 2025, 11(1): 12 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Hosseinpour Feizi A A, Shoaran M, Dastgiri S, Tavakolifar Y, Hiradfar A A, Amri F et al . Survival and Prognosis of Children and Adolescents with Hematological Malignancies with Liver Involvement Undergoing Chemotherapy. CJP 2025; 11 (1) : 12
URL: http://caspianjp.ir/article-1-273-en.html
URL: http://caspianjp.ir/article-1-273-en.html
Abbas Ali Hosseinpour Feizi 
, Maryam Shoaran , Saeed Dastgiri , Yousef Tavakolifar , Amir Ataollah Hiradfar , Fatemeh Amri * , Parviz Amri
, Maryam Shoaran , Saeed Dastgiri , Yousef Tavakolifar , Amir Ataollah Hiradfar , Fatemeh Amri * , Parviz Amri
Department of Pediatrics, School of Medicine Tabriz University of Medical Sciences, Tabriz, Iran , Fatemeamri22@gmail.com
Abstract: (30 Views)
Background and Objective: Liver disorders in hematological malignancies cause treatment delays and, as a result, disease recurrence. The aim of this study was to evaluate the survival and prognosis of children and adolescents with hematological malignancies and liver involvement after chemotherapy.
Methods: This cross-sectional study was conducted in the Hematology and Oncology Department of Mardani Azar Children’s Hospital, Tabriz University of Medical Sciences, by reviewing the files of patients hospitalized from December 22, 2021 to December 22, 2023. The study included hospitalized children with hematological malignancies. Demographic information, treatment stage, and liver test results were recorded before and after chemotherapy. Survival modeling was performed from the time of diagnosis to the occurrence of outcomes, including relapse, disease remission, complete recovery, and mortality, using the Kaplan–Meier method. Data were statistically analyzed using SPSS 26. A value of P<0.05 was considered significant.
Findings: In this study, out of 150 patients, 55 (36%) had elevated liver enzyme levels. During the clinical and laboratory follow-up, one patient achieved complete recovery, 27 patients had remission, and 21 patients experienced relapse. The mortality rate was 1.9%. The survival rate among patients with liver damage was 87%. The survival probability for patients with liver damage was 0.95 after 7 months, 0.89 after 10 months, and decreased to 0.45 after 21 months.
Conclusion: The mortality rate was higher in patients whose treatment was discontinued due to prolonged elevation of liver enzymes than in those whose liver damage improved and who continued malignant treatment.
Methods: This cross-sectional study was conducted in the Hematology and Oncology Department of Mardani Azar Children’s Hospital, Tabriz University of Medical Sciences, by reviewing the files of patients hospitalized from December 22, 2021 to December 22, 2023. The study included hospitalized children with hematological malignancies. Demographic information, treatment stage, and liver test results were recorded before and after chemotherapy. Survival modeling was performed from the time of diagnosis to the occurrence of outcomes, including relapse, disease remission, complete recovery, and mortality, using the Kaplan–Meier method. Data were statistically analyzed using SPSS 26. A value of P<0.05 was considered significant.
Findings: In this study, out of 150 patients, 55 (36%) had elevated liver enzyme levels. During the clinical and laboratory follow-up, one patient achieved complete recovery, 27 patients had remission, and 21 patients experienced relapse. The mortality rate was 1.9%. The survival rate among patients with liver damage was 87%. The survival probability for patients with liver damage was 0.95 after 7 months, 0.89 after 10 months, and decreased to 0.45 after 21 months.
Conclusion: The mortality rate was higher in patients whose treatment was discontinued due to prolonged elevation of liver enzymes than in those whose liver damage improved and who continued malignant treatment.
Article number: 12
Send email to the article author
| Rights and Permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
